PharMerica upgraded

Credit Suisse upgrades PharMerica (PMC) to Outperform and raises its price target from $19 to $30.

Analyst Glen Santangelo cites the company's accelerating growth profile as the main reason for his bullish outlook.

Consensus estimates for 2014 and 2015 are $1.47/share on revenues of $1.68B and $1.75/share on revenues of $1.72B, respectively.

282 mutual funds have positions.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs